Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial.

Date publication

décembre 2025

Journal

JAMA network open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GUIHARD Sébastien , Dr FAIVRE Jean-Christophe , Dr VULQUIN Noémie

Tous les auteurs :
Biau J, Sun X, Liem X, Faivre JC, Eker E, Blanchard P, Tao Y, Doré M, Maingon P, Vulquin N, Alfonsi M, Thureau S, Huguet F, Racadot S, Thivat E, Molnar I, Boisselier P, Guihard S, Gallocher O, Dupin C, Batard S, Bourhis J, Lapeyre M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41632122

Résumé

Postoperative radiotherapy (mainly fractionated intensity-modulated radiotherapy) is indicated after surgery for early-stage oral cavity squamous cell carcinoma (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC) in the presence of high-risk margins. Postoperative brachytherapy is a treatment option, but it is not always feasible; stereotactic body radiotherapy (SBRT) may offer a noninvasive alternative.

Mots clés

Humans, Male, Female, Radiosurgery, adverse effects, Middle Aged, Oropharyngeal Neoplasms, surgery, Aged, Mouth Neoplasms, surgery, France, Radiotherapy, Intensity-Modulated, adverse effects, Adult, Aged, 80 and over, Squamous Cell Carcinoma of Head and Neck, radiotherapy, Carcinoma, Squamous Cell, radiotherapy

Référence

JAMA Netw Open. 2025 12 1;8(12):e2549975